25 XP   0   0   10

Almirall
Buy, Hold or Sell?

Let's analyse Almirall together

PenkeI guess you are interested in Almirall. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Almirall. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Almirall

I send you an email if I find something interesting about Almirall.

Quick analysis of Almirall (30 sec.)










What can you expect buying and holding a share of Almirall? (30 sec.)

How much money do you get?

How much money do you get?
‚ā¨0.05
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
‚ā¨7.00
Expected worth in 1 year
‚ā¨9.76
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
‚ā¨2.82
Return On Investment
28.8%

For what price can you sell your share?

Current Price per Share
‚ā¨9.77
Expected price per share
‚ā¨8.2092457627119 - ‚ā¨9.9595907284768
How sure are you?
50%

1. Valuation of Almirall (5 min.)




Live pricePrice per Share (EOD)

‚ā¨9.77

Intrinsic Value Per Share

‚ā¨-7.48 - ‚ā¨17.68

Total Value Per Share

‚ā¨-0.49 - ‚ā¨24.68

2. Growth of Almirall (5 min.)




Is Almirall growing?

Current yearPrevious yearGrowGrow %
How rich?$1.5b$1.4b$155.7m9.9%

How much money is Almirall making?

Current yearPrevious yearGrowGrow %
Making money-$41.4m$4.6m-$46m-111.1%
Net Profit Margin-4.3%0.5%--

How much money comes from the company's main activities?

3. Financial Health of Almirall (5 min.)




What can you expect buying and holding a share of Almirall? (5 min.)

Welcome investor! Almirall's management wants to use your money to grow the business. In return you get a share of Almirall.

What can you expect buying and holding a share of Almirall?

First you should know what it really means to hold a share of Almirall. And how you can make/lose money.

Speculation

The Price per Share of Almirall is ‚ā¨9.77. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Almirall.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Almirall, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ‚ā¨7.00. Based on the TTM, the Book Value Change Per Share is ‚ā¨0.69 per quarter. Based on the YOY, the Book Value Change Per Share is ‚ā¨0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ‚ā¨0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Almirall.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share‚ā¨% of Price per Share
Usd Eps-0.20-2.0%-0.20-2.0%0.020.2%0.111.1%0.282.8%
Usd Book Value Change Per Share0.747.6%0.747.6%0.171.7%0.282.9%0.303.0%
Usd Dividend Per Share0.010.1%0.010.1%0.060.7%0.050.6%0.111.1%
Usd Total Gains Per Share0.767.8%0.767.8%0.232.4%0.333.4%0.404.1%
Usd Price Per Share9.07-9.07-9.73-11.70-13.26-
Price to Earnings Ratio-45.78--45.78-441.72-79.55-50.49-
Price-to-Total Gains Ratio11.97-11.97-41.93--56.69--18.91-
Price to Book Ratio1.20-1.20-1.43-1.72-1.94-
Price-to-Total Gains Ratio11.97-11.97-41.93--56.69--18.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.519359
Number of shares95
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.05
Usd Book Value Change Per Share0.740.28
Usd Total Gains Per Share0.760.33
Gains per Quarter (95 shares)72.0231.75
Gains per Year (95 shares)288.07127.01
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1528327821106117
21056656641213244
31584985462319371
4201132114283425498
52514151430104531625
63016981718124638752
73519812006145744879
841226422941668501006
946254725821879561133
10512830287020710631260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%7.03.00.070.0%15.04.00.078.9%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%13.06.00.068.4%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%14.05.00.073.7%

Fundamentals of Almirall

About Almirall

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Fundamental data was last updated by Penke on 2024-05-25 19:47:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Almirall.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit¬†Almirall earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare¬†Almirall to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -4.3%¬†means that¬†€-0.04 for each €1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Almirall:

  • The MRQ is -4.3%. The company is making a loss. -1
  • The TTM is -4.3%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-4.3%TTM-4.3%0.0%
TTM-4.3%YOY0.5%-4.8%
TTM-4.3%5Y1.7%-5.9%
5Y1.7%10Y5.5%-3.8%
1.1.2. Return on Assets

Shows how efficient Almirall is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Almirall to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • -1.6% Return on Assets means that¬†Almirall generated¬†€-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Almirall:

  • The MRQ is -1.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.6%TTM-1.6%0.0%
TTM-1.6%YOY0.2%-1.8%
TTM-1.6%5Y0.9%-2.5%
5Y0.9%10Y1.9%-1.1%
1.1.3. Return on Equity

Shows how efficient Almirall is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Almirall to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • -2.6% Return on Equity means Almirall generated €-0.03¬†for each¬†€1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Almirall:

  • The MRQ is -2.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.6%TTM-2.6%0.0%
TTM-2.6%YOY0.3%-3.0%
TTM-2.6%5Y1.7%-4.3%
5Y1.7%10Y3.6%-1.9%

1.2. Operating Efficiency of Almirall.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Almirall is operating .

  • Measures how much profit Almirall makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Almirall to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 4.8%¬†means the company generated €0.05 ¬†for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Almirall:

  • The MRQ is 4.8%. The company is operating less efficient.
  • The TTM is 4.8%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ4.8%TTM4.8%0.0%
TTM4.8%YOY7.6%-2.8%
TTM4.8%5Y9.7%-4.9%
5Y9.7%10Y16.3%-6.6%
1.2.2. Operating Ratio

Measures how efficient Almirall is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.95 means that the operating costs are €0.95 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Almirall:

  • The MRQ is 0.946. The company is less efficient in keeping operating costs low.
  • The TTM is 0.946. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.946TTM0.9460.000
TTM0.946YOY0.920+0.026
TTM0.9465Y0.795+0.151
5Y0.79510Y0.781+0.014

1.3. Liquidity of Almirall.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Almirall is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.05¬†means the company has €2.05 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Almirall:

  • The MRQ is 2.047. The company is able to pay all its short-term debts. +1
  • The TTM is 2.047. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.047TTM2.0470.000
TTM2.047YOY2.013+0.034
TTM2.0475Y1.675+0.372
5Y1.67510Y2.041-0.366
1.3.2. Quick Ratio

Measures if Almirall is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Almirall to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.53¬†means the company can pay off €1.53 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Almirall:

  • The MRQ is 1.525. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.525. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.525TTM1.5250.000
TTM1.525YOY1.488+0.038
TTM1.5255Y1.245+0.280
5Y1.24510Y1.976-0.731

1.4. Solvency of Almirall.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Almirall assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Almirall to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.38¬†means that Almirall assets are¬†financed with 38.4% credit (debt) and the remaining percentage (100% - 38.4%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Almirall:

  • The MRQ is 0.384. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.384. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.384TTM0.3840.000
TTM0.384YOY0.386-0.002
TTM0.3845Y0.415-0.031
5Y0.41510Y0.441-0.026
1.4.2. Debt to Equity Ratio

Measures if Almirall is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Almirall to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 62.3% means that company has €0.62 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Almirall:

  • The MRQ is 0.623. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.623. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.623TTM0.6230.000
TTM0.623YOY0.629-0.006
TTM0.6235Y0.716-0.093
5Y0.71610Y0.799-0.083

2. Market Valuation of Almirall

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures¬†how much money you pay¬†for each share for¬†every €1 in earnings Almirall generates.

  • Above 15 is considered overpriced but¬†always compare¬†Almirall to the¬†Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -45.78 means the investor is paying €-45.78¬†for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Almirall:

  • The EOD is -53.083. Based on the earnings, the company is expensive. -2
  • The MRQ is -45.775. Based on the earnings, the company is expensive. -2
  • The TTM is -45.775. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-53.083MRQ-45.775-7.308
MRQ-45.775TTM-45.7750.000
TTM-45.775YOY441.718-487.494
TTM-45.7755Y79.552-125.327
5Y79.55210Y50.490+29.062
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Almirall:

  • The EOD is -31.050. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -26.776. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -26.776. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-31.050MRQ-26.776-4.275
MRQ-26.776TTM-26.7760.000
TTM-26.776YOY48.962-75.737
TTM-26.7765Y16.862-43.638
5Y16.86210Y18.811-1.949
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Almirall is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.20 means the investor is paying €1.20¬†for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Almirall:

  • The EOD is 1.397. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.204. Based on the equity, the company is underpriced. +1
  • The TTM is 1.204. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.397MRQ1.204+0.192
MRQ1.204TTM1.2040.000
TTM1.204YOY1.434-0.230
TTM1.2045Y1.724-0.520
5Y1.72410Y1.935-0.211
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Almirall compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6920.6920%0.156+343%0.260+166%0.275+152%
Book Value Per Share--6.9966.9960%6.304+11%6.359+10%6.358+10%
Current Ratio--2.0472.0470%2.013+2%1.675+22%2.041+0%
Debt To Asset Ratio--0.3840.3840%0.386-1%0.415-8%0.441-13%
Debt To Equity Ratio--0.6230.6230%0.629-1%0.716-13%0.799-22%
Dividend Per Share--0.0120.0120%0.059-79%0.051-76%0.101-88%
Eps---0.184-0.1840%0.020-999%0.100-283%0.256-172%
Free Cash Flow Per Share---0.315-0.3150%0.185-270%0.349-190%0.315-200%
Free Cash Flow To Equity Per Share--0.4890.4890%-0.031+106%0.202+142%0.273+79%
Gross Profit Margin--11.17211.1720%-2.213+120%2.401+365%1.626+587%
Intrinsic Value_10Y_max--17.684--------
Intrinsic Value_10Y_min---7.485--------
Intrinsic Value_1Y_max--0.657--------
Intrinsic Value_1Y_min---0.028--------
Intrinsic Value_3Y_max--2.824--------
Intrinsic Value_3Y_min---0.710--------
Intrinsic Value_5Y_max--6.015--------
Intrinsic Value_5Y_min---2.072--------
Market Cap2043698291.840+14%1762349857.6001762349857.6000%1890996167.680-7%2272751478.080-22%2576796049.952-32%
Net Profit Margin---0.043-0.0430%0.005-964%0.017-359%0.055-178%
Operating Margin--0.0480.0480%0.076-37%0.097-51%0.163-71%
Operating Ratio--0.9460.9460%0.920+3%0.795+19%0.781+21%
Pb Ratio1.397+14%1.2041.2040%1.434-16%1.724-30%1.935-38%
Pe Ratio-53.083-16%-45.775-45.7750%441.718-110%79.552-158%50.490-191%
Price Per Share9.770+14%8.4258.4250%9.040-7%10.865-22%12.319-32%
Price To Free Cash Flow Ratio-31.050-16%-26.776-26.7760%48.962-155%16.862-259%18.811-242%
Price To Total Gains Ratio13.877+14%11.96611.9660%41.934-71%-56.687+574%-18.912+258%
Quick Ratio--1.5251.5250%1.488+3%1.245+23%1.976-23%
Return On Assets---0.016-0.0160%0.002-913%0.009-291%0.019-185%
Return On Equity---0.026-0.0260%0.003-910%0.017-255%0.036-174%
Total Gains Per Share--0.7040.7040%0.216+227%0.310+127%0.376+87%
Usd Book Value--1575642780.0001575642780.0000%1419860440.500+11%1432292234.040+10%1431920880.210+10%
Usd Book Value Change Per Share--0.7450.7450%0.168+343%0.280+166%0.296+152%
Usd Book Value Per Share--7.5327.5320%6.788+11%6.847+10%6.845+10%
Usd Dividend Per Share--0.0130.0130%0.064-79%0.055-76%0.109-88%
Usd Eps---0.198-0.1980%0.022-999%0.108-283%0.275-172%
Usd Free Cash Flow---70867317.300-70867317.3000%41584307.400-270%78556032.000-190%71050786.980-200%
Usd Free Cash Flow Per Share---0.339-0.3390%0.199-270%0.376-190%0.340-200%
Usd Free Cash Flow To Equity Per Share--0.5270.5270%-0.033+106%0.218+142%0.294+79%
Usd Market Cap2200449950.824+14%1897522091.6781897522091.6780%2036035573.741-7%2447071516.449-22%2774436306.983-32%
Usd Price Per Share10.519+14%9.0719.0710%9.733-7%11.698-22%13.263-32%
Usd Profit---41452950.000-41452950.0000%4609352.700-999%22634602.740-283%57555859.860-172%
Usd Revenue--967737960.000967737960.0000%929459121.600+4%1089498948.240-11%939784351.590+3%
Usd Total Gains Per Share--0.7580.7580%0.232+227%0.334+127%0.405+87%
 EOD+6 -2MRQTTM+0 -0YOY+19 -175Y+19 -1710Y+19 -17

3.2. Fundamental Score

Let's check the fundamental score of Almirall based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-53.083
Price to Book Ratio (EOD)Between0-11.397
Net Profit Margin (MRQ)Greater than0-0.043
Operating Margin (MRQ)Greater than00.048
Quick Ratio (MRQ)Greater than11.525
Current Ratio (MRQ)Greater than12.047
Debt to Asset Ratio (MRQ)Less than10.384
Debt to Equity Ratio (MRQ)Less than10.623
Return on Equity (MRQ)Greater than0.15-0.026
Return on Assets (MRQ)Greater than0.05-0.016
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Almirall based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.396
Ma 20Greater thanMa 509.614
Ma 50Greater thanMa 1008.875
Ma 100Greater thanMa 2008.541
OpenGreater thanClose9.750
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets2,374,985
Total Liabilities911,585
Total Stockholder Equity1,463,400
 As reported
Total Liabilities 911,585
Total Stockholder Equity+ 1,463,400
Total Assets = 2,374,985

Assets

Total Assets2,374,985
Total Current Assets718,662
Long-term Assets1,656,323
Total Current Assets
Cash And Cash Equivalents 387,954
Short-term Investments 136
Net Receivables 147,192
Inventory 167,370
Other Current Assets 16,010
Total Current Assets  (as reported)718,662
Total Current Assets  (calculated)718,662
+/-0
Long-term Assets
Property Plant Equipment 184,303
Goodwill 315,966
Intangible Assets 951,415
Long-term Assets Other 136
Long-term Assets  (as reported)1,656,323
Long-term Assets  (calculated)1,451,820
+/- 204,503

Liabilities & Shareholders' Equity

Total Current Liabilities351,075
Long-term Liabilities560,510
Total Stockholder Equity1,463,400
Total Current Liabilities
Short-term Debt 17,210
Short Long Term Debt 11,004
Accounts payable 181,354
Other Current Liabilities 89,349
Total Current Liabilities  (as reported)351,075
Total Current Liabilities  (calculated)298,917
+/- 52,158
Long-term Liabilities
Long term Debt 348,431
Capital Lease Obligations 43,811
Long-term Liabilities Other 10,349
Long-term Liabilities  (as reported)560,510
Long-term Liabilities  (calculated)402,591
+/- 157,919
Total Stockholder Equity
Common Stock25,127
Retained Earnings -38,474
Accumulated Other Comprehensive Income 895,265
Other Stockholders Equity 581,482
Total Stockholder Equity (as reported)1,463,400
Total Stockholder Equity (calculated)1,463,400
+/-0
Other
Capital Stock25,127
Cash and Short Term Investments 388,090
Common Stock Shares Outstanding 196,992
Current Deferred Revenue63,162
Liabilities and Stockholders Equity 2,374,985
Net Debt 15,292
Net Invested Capital 1,822,835
Net Working Capital 367,587
Property Plant and Equipment Gross 571,234
Short Long Term Debt Total 403,246



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-31
> Total Assets 
797,266
849,035
1,202,371
1,114,173
1,439,109
1,396,400
1,483,000
1,536,700
1,456,607
1,356,107
1,772,721
2,540,401
2,532,345
2,818,528
2,176,445
2,389,506
2,439,787
2,291,114
2,141,744
2,147,691
2,374,985
2,374,9852,147,6912,141,7442,291,1142,439,7872,389,5062,176,4452,818,5282,532,3452,540,4011,772,7211,356,1071,456,6071,536,7001,483,0001,396,4001,439,1091,114,1731,202,371849,035797,266
   > Total Current Assets 
0
0
754,260
663,453
451,606
435,300
504,000
528,000
458,655
310,440
334,599
1,107,266
1,147,083
738,553
515,363
414,370
476,614
489,750
499,274
552,718
718,662
718,662552,718499,274489,750476,614414,370515,363738,5531,147,0831,107,266334,599310,440458,655528,000504,000435,300451,606663,453754,26000
       Cash And Cash Equivalents 
35,748
36,325
518,655
23,043
44,898
186,100
259,700
312,900
38,717
35,592
80,855
297,927
597,954
249,499
211,542
85,190
117,212
159,642
206,487
248,380
387,954
387,954248,380206,487159,642117,21285,190211,542249,499597,954297,92780,85535,59238,717312,900259,700186,10044,89823,043518,65536,32535,748
       Short-term Investments 
201,161
283,605
455,697
398,389
145,052
143,681
220,148
250,245
190,208
16,699
8,356
456,507
270,042
217,212
68,684
1,080
82
6,025
899
443
136
1364438996,025821,08068,684217,212270,042456,5078,35616,699190,208250,245220,148143,681145,052398,389455,697283,605201,161
       Net Receivables 
144,167
127,547
93,899
145,583
146,452
107,900
120,400
103,800
129,379
157,250
137,572
265,652
188,572
176,151
148,317
231,776
245,112
184,039
161,882
159,225
147,192
147,192159,225161,882184,039245,112231,776148,317176,151188,572265,652137,572157,250129,379103,800120,400107,900146,452145,58393,899127,547144,167
       Other Current Assets 
1,001
1,019
141,949
2,276
3,466
28,800
26,200
23,400
7,144
8,493
10,074
6,161
3,391
4,651
3,980
4,086
8,212
9,991
11,531
14,722
16,010
16,01014,72211,5319,9918,2124,0863,9804,6513,3916,16110,0748,4937,14423,40026,20028,8003,4662,276141,9491,0191,001
   > Long-term Assets 
0
0
448,111
450,720
987,503
961,100
979,000
1,008,700
997,952
1,045,667
1,438,122
1,433,135
1,385,262
2,079,975
1,661,082
1,975,136
1,963,173
1,801,364
1,642,470
1,594,973
1,656,323
1,656,3231,594,9731,642,4701,801,3641,963,1731,975,1361,661,0822,079,9751,385,2621,433,1351,438,1221,045,667997,9521,008,700979,000961,100987,503450,720448,11100
       Property Plant Equipment 
72,019
97,072
147,292
151,488
179,340
175,700
169,100
154,800
152,131
157,037
161,306
132,127
127,795
132,298
128,317
115,235
135,691
132,868
137,446
162,704
184,303
184,303162,704137,446132,868135,691115,235128,317132,298127,795132,127161,306157,037152,131154,800169,100175,700179,340151,488147,29297,07272,019
       Goodwill 
56,205
27,565
39,955
47,308
274,258
273,500
272,700
271,900
271,086
270,293
336,215
338,769
347,310
432,765
341,815
315,966
315,966
315,966
315,966
315,966
315,966
315,966315,966315,966315,966315,966315,966341,815432,765347,310338,769336,215270,293271,086271,900272,700273,500274,25847,30839,95527,56556,205
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
7,964
9,376
28,602
14,835
12,969
0
103,184
0
0
0
0
0000103,184012,96914,83528,6029,3767,9640000000000
       Intangible Assets 
137,374
99,281
73,674
85,238
383,448
342,700
352,800
382,800
353,070
358,207
595,125
444,420
412,693
992,996
730,316
1,121,215
1,139,015
1,009,536
916,056
898,677
951,415
951,415898,677916,0561,009,5361,139,0151,121,215730,316992,996412,693444,420595,125358,207353,070382,800352,800342,700383,44885,23873,67499,281137,374
       Long-term Assets Other 
0
0
90,031
1,308
1,317
169,200
184,400
10,200
190,208
15,235
23,734
457,009
271,002
216,804
57,695
6,564
103,184
86,518
80,502
34,655
136
13634,65580,50286,518103,1846,56457,695216,804271,002457,00923,73415,235190,20810,200184,400169,2001,3171,30890,03100
> Total Liabilities 
344,965
336,658
303,852
350,960
865,454
1,396,400
732,000
717,400
601,894
432,440
884,387
1,200,835
1,069,763
1,298,248
1,042,765
1,197,757
1,159,601
988,148
855,705
828,976
911,585
911,585828,976855,705988,1481,159,6011,197,7571,042,7651,298,2481,069,7631,200,835884,387432,440601,894717,400732,0001,396,400865,454350,960303,852336,658344,965
   > Total Current Liabilities 
187,864
185,704
214,834
211,967
274,742
239,100
237,900
213,100
413,561
249,481
398,084
361,193
301,556
371,585
348,407
244,068
316,527
474,559
280,993
274,613
351,075
351,075274,613280,993474,559316,527244,068348,407371,585301,556361,193398,084249,481413,561213,100237,900239,100274,742211,967214,834185,704187,864
       Short-term Debt 
0
0
7,291
8,653
66,435
0
0
0
202,222
3,665
29,774
10,569
13,783
7,500
1,943
3,259
10,982
253,518
18,445
16,714
17,210
17,21016,71418,445253,51810,9823,2591,9437,50013,78310,56929,7743,665202,22200066,4358,6537,29100
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
297,008
14,378
17,618
11,343
2,015
3,666
4,107
247,942
14,481
11,614
11,004
11,00411,61414,481247,9424,1073,6662,01511,34317,61814,378297,0080000000000
       Accounts payable 
116,998
125,137
138,516
143,105
149,803
154,411
142,687
136,281
149,198
183,696
198,385
218,162
225,306
237,261
140,604
191,019
222,478
162,143
177,800
184,287
181,354
181,354184,287177,800162,143222,478191,019140,604237,261225,306218,162198,385183,696149,198136,281142,687154,411149,803143,105138,516125,137116,998
       Other Current Liabilities 
62,231
54,377
38,702
16,116
2,488
239,100
237,900
213,100
40,021
5,617
39,345
32,738
6,194
49,521
193,221
35,504
41,058
4,093
31,288
13,779
89,349
89,34913,77931,2884,09341,05835,504193,22149,5216,19432,73839,3455,61740,021213,100237,900239,1002,48816,11638,70254,37762,231
   > Long-term Liabilities 
0
0
89,018
138,993
590,712
504,300
494,100
504,300
188,333
182,959
486,303
839,642
768,207
926,663
694,358
953,689
843,074
513,589
574,712
554,363
560,510
560,510554,363574,712513,589843,074953,689694,358926,663768,207839,642486,303182,959188,333504,300494,100504,300590,712138,99389,01800
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
237,827
373,854
387,161
0
0387,161373,854237,82700000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-7,291
-8,653
-66,435
0
0
0
-202,222
-3,665
-29,774
-10,569
-13,783
-7,500
-1,943
-3,259
7,625
-233,774
1,995
22,321
26,601
26,60122,3211,995-233,7747,625-3,259-1,943-7,500-13,783-10,569-29,774-3,665-202,222000-66,435-8,653-7,29100
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
34,404
4,260
4,367
1
1
0
0
10,349
10,34900114,3674,26034,4040000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
54,670
3,844
3,533
83,702
29,844
30,270
30,657
35,362
19,323
80,099
0
080,09919,32335,36230,65730,27029,84483,7023,5333,84454,6700000000000
> Total Stockholder Equity
452,301
512,377
898,519
763,213
573,655
653,000
751,000
819,300
854,713
923,667
888,334
1,339,566
1,462,582
1,520,280
1,133,680
1,191,749
1,280,186
1,302,966
1,286,039
1,318,715
1,463,400
1,463,4001,318,7151,286,0391,302,9661,280,1861,191,7491,133,6801,520,2801,462,5821,339,566888,334923,667854,713819,300751,000653,000573,655763,213898,519512,377452,301
   Common Stock
21,516
21,516
21,516
18,972
19,932
19,932
19,932
19,932
19,932
20,463
20,754
20,754
20,754
20,754
20,754
20,862
20,947
21,374
21,573
21,782
25,127
25,12721,78221,57321,37420,94720,86220,75420,75420,75420,75420,75420,46319,93219,93219,93219,93219,93218,97221,51621,51621,516
   Retained Earnings 
79,482
89,839
117,725
147,250
131,206
140,123
155,480
122,590
84,166
76,291
-33,717
448,429
131,826
75,479
-303,961
77,674
105,909
74,280
-40,859
4,281
-38,474
-38,4744,281-40,85974,280105,90977,674-303,96175,479131,826448,429-33,71776,29184,166122,590155,480140,123131,206147,250117,72589,83979,482
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
273,889
295,785
317,315
0
0317,315295,785273,88900000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
759,278
596,991
422,517
653,000
751,000
819,300
750,615
826,913
901,297
870,383
1,310,002
1,424,047
1,416,887
1,093,213
133,329
197,348
334,513
310,482
581,482
581,482310,482334,513197,348133,3291,093,2131,416,8871,424,0471,310,002870,383901,297826,913750,615819,300751,000653,000422,517596,991759,27800



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.